CrownBio develops mouse strains with human PD-1 for mAb testing

By Gareth Macdonald

- Last updated on GMT


Related tags Immune system

Crown Bioscience has developed humanized mouse cancer models which it claims provide biologic drug developers with an improved means of assessing efficacy.

The HuGEMM range of cancer models comprises strains of mouse in which the gene encoding a protein called PD-1, a key modulator of immune response, has been replaced​ with the gene encoding the human version of the protein.

In healthy cells, PD-1 prevents autoimmunity by promoting apoptosis – programmed cell death – in antigen specific T cells and reducing it in suppressor T cells.

PD-1 is a target for drug developers, with the theory being that inhibiting its immunosuppressive function will prompt the immune system to attack tumour cells.

Mice also have a PD-1 protein.

However, the difference between human and mouse PD-1 means that, until now, mouse models have not been very useful for assessing monoclonal antibody (mAb) candidates according to Jean-Pierre Wery, Crown Bioscience president.

With HuGEMM, there is now a robust model system in place to enable scientists to assess the efficacy of human biologic therapeutics directly without resorting to mouse surrogates​.”

The models were developed in collaboration with CrownBio’s partner, Nanjing Galaxy Biopharmaceutical.

According to CrownBio the partnership “is expected to continue to advance both organizations’ research capabilities in immuno-oncology​.”

The launch of the new cancer models follows a month after CrownBio bolstered its cardiovascular and metabolic disease model offering through the acquisition of PreClinOmics.

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Content provided by Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us


View more